Daclizumab (Daklizumab)
| Use attributes for filter ! | |
| CAS ID | 152923-56-3 |
|---|---|
| Bioavailability | 90% |
| Target | CD25 |
| Trade name | Zinbryta (multiple sclerosis); Zenapax (acute transplant rejection, discontinued in 2009) |
| License data | EMA |
| ATC code | L04AC01 (WHO) |
| Music groups | Basiliximab |
| Alemtuzumab | |
| Natalizumab | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951153 |
About Daclizumab (Daklizumab)
Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis. Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.